Drug reference

C1-esterase inhibitor

Monoclonal Antibody · Treatment of hereditary angioedema

Also known as Cinryze, Berinert, C1-INH

Monoclonal AntibodyTreatment of hereditary angioedema

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

C1-esterase inhibitor (C1-INH) is a plasma protein that regulates the complement and contact systems. Hereditary angioedema (HAE) results from a deficiency or dysfunction of endogenous C1-INH, leading to uncontrolled activation of these systems and increased bradykinin production, which mediates angioedema attacks. Cinryze provides exogenous C1-esterase inhibitor, thereby replacing the deficient protein to regulate these pathways and prevent or treat HAE attacks.

Indications

Acute attacks of hereditary angioedema (under expert supervision)Short-term prophylaxis of hereditary angioedema before dental, medical, or surgical procedures (under expert supervision)Long-term prophylaxis of severe, recurrent attacks of hereditary angioedema where acute treatment is inadequate, or when oral prophylaxis is inadequate or not tolerated (under expert supervision)

Dosing

Adult: Acute attacks of hereditary angioedema: 1000 units for 1 dose by slow intravenous injection, dose may be repeated if necessary after 60 minutes (or sooner for patients experiencing laryngeal attacks or if treatment initiation is delayed). Short-term prophylaxis: 1000 units for 1 dose by slow intravenous injection, to be administered up to 24 hours before procedure.…